The Latest Breaking News from Pfizer

Pfizer (NYSE: PFE) and its partner, BioNTech (NASDAQ: BNTX) announced that they have completed the submission of a regulatory application to the European Medicines Agency (EMA), which seeks authorization for thei

Twice as many people currently have covid as have the common cold as cases rocket

Adults who haven't gotten any COVID-19 shots should consider the new option, the agency said Tuesday. The spike protein vaccine is more typical than the mRNA types being broadly used against COVID.

Novavax Inc.’s shares surged after its COVID-19 vaccine won backing from a panel of U.S. public health advisers, a crucial step in providing officials with another tool against the virus as cases start to rise again.

Two-dose shot will becomes fourth one to gain full approval later this week

Government advisers say U.S. adults who haven’t gotten any COVID-19 shots yet should consider a new option from Novavax

Patients with prescriptions for antiviral drugs after catching COVID-19 are struggling to get them filled at pharmacies across Queensland, a medical association says, as increased illegibility increases demand on stocks.

How Sotiris Missailidis, head of R&D in Brazil's vaccine agency, used the COVID crisis to push through a game-changing effort for middle-income countries to invent their own mRNA vaccine.

‘Continual updating of our vaccinations and booster shots is critical,’ scientists say

Australia has used less than a quarter of the hundreds of millions of COVID-19 vaccine doses it bought. What will happen to the rest?

ORLANDO, Fla. — Scientists have suggested that once vaccines and treatment for COVID-19 became widely available, a surge might not require more than the basic precautions practiced during flu season. With the development of vaccines, pre-exposure treatment such as Evushield and post-exposure treatment such as Paxlovid, it’s natural to ask…